These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
162 related items for PubMed ID: 10192973
1. Nebivolol versus enalapril in essential hypertension: a long-term double-blind comparative trial. Van Nueten L, Rishøj Nielsen M, Vertommen C, Dupont AG, Robertson JI. Acta Clin Belg; 1999; 54(1):19-25. PubMed ID: 10192973 [Abstract] [Full Text] [Related]
2. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. J Hum Hypertens; 1997 Dec; 11(12):813-9. PubMed ID: 9468009 [Abstract] [Full Text] [Related]
3. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. J Hypertens; 2006 Jul; 24(7):1397-403. PubMed ID: 16794490 [Abstract] [Full Text] [Related]
4. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Van Nueten L, Lacourcière Y, Vyssoulis G, Korlipara K, Marcadet DM, Dupont AG, Robertson JI. Am J Ther; 1998 Jul; 5(4):237-43. PubMed ID: 10099065 [Abstract] [Full Text] [Related]
9. Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension. Simon G, Johnson ML. Clin Exp Hypertens; 1993 May; 15(3):501-9. PubMed ID: 8098243 [Abstract] [Full Text] [Related]
11. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. Van Nueten L, Taylor FR, Robertson JI. J Hum Hypertens; 1998 Feb; 12(2):135-40. PubMed ID: 9504355 [Abstract] [Full Text] [Related]
12. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Papademetriou V. Am J Cardiol; 2009 Jan 15; 103(2):273-8. PubMed ID: 19121451 [Abstract] [Full Text] [Related]
14. Nebivolol: a new beta blocker on the horizon. Katira R, Chauhan A. Indian Heart J; 2000 Jan 15; 52(1):86-8. PubMed ID: 10820942 [No Abstract] [Full Text] [Related]
15. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Germino FW. Clin Ther; 2009 Sep 15; 31(9):1946-56. PubMed ID: 19843484 [Abstract] [Full Text] [Related]
16. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Weiss RJ, Stapff M, Lin Y. Am J Cardiovasc Drugs; 2013 Apr 15; 13(2):129-40. PubMed ID: 23519546 [Abstract] [Full Text] [Related]
17. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Pesant Y, Marc-Aurèle J, Bielmann P, Alaupovic P, Cartier P, Bichet D, Thibault G, Lupien PJ. Am J Ther; 1999 May 15; 6(3):137-47. PubMed ID: 10423656 [Abstract] [Full Text] [Related]
18. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study]. von Fallois J, Faülhaber HD. Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():77-82. PubMed ID: 15700490 [Abstract] [Full Text] [Related]